Clinical trial · Interventional
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma in Remission | Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| peripheral blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed
- description
- in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV
- interventionNames
- Other: peripheral blood sampling
Primary outcomes (2)
- measure
- evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
- timeFrame
- through study completion, an average of 2 year
- description
- Determine the biological age of patients
- measure
- DNA methylation (methylation rate)
- timeFrame
- through study completion, an average of 2 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma * Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy * Patients of both sexes aged ≥ 18 years at enrollment * Signature of informed consent Exclusion Criteria: * Concomitant second neoplasm
References
Publications (0)
Data not yet available